Why These 10 Stocks Soared Today

6. Verona Pharma PLC (NASDAQ:VRNA)

Verona Pharma extended its rally for an eighth straight day on Tuesday, adding 6.37 percent to end at $73.21 apiece after the company posted an impressive earnings performance during the first three months of the year.

In its earnings release, Verona Pharma PLC (NASDAQ:VRNA) said that it narrowed its net loss by 36.8 percent to $16.3 million from $25.79 million in the same period a year earlier.

Net revenues stood at $76.3 million, primarily driven by $71.3 million in net sales from Ohtuvayre, the company’s maintenance treatment of COPD.

In February this year, Verona Pharma PLC (NASDAQ:VRNA), through its partner Nuance Pharma, secured the green light of the Macau government to sell Ohtuvayre in the special administrative region.

Commenting on its strong performance, VRNA President and CEO David Zaccardelli said: “We are extremely pleased to report that for the first time, Verona’s quarterly revenue exceeded our operating expenses, excluding non-cash charges. We believe we are in a robust financial position to continue commercializing Ohtuvayre, advance our clinical pipeline, and implement our global strategy.”